By Fineline Cube The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) issued the Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments) on July 14, 2026. The draft guideline opens a one-month public comment period and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.
Regulatory Framework | Key Provisions
| Aspect | Requirement |
|---|---|
| Comment Period | One month from July 14, 2026 |
| Primary Evidence Source | Real-world research data |
| Target Population | Pediatric patients in China |
| Drug Status Requirement | Already marketed in China with ≥2 years clinical use |
| Implementation Goal | Streamlined, efficient, and implementable regulatory pathway |
Eligibility Criteria for Drug Candidates
Clinical Urgency
- Drugs urgently needed in pediatric clinical practice in China
- Priority support for drugs included in the Catalogue of Drugs Encouraged for R&D and Application in Children
- Focus on treatments for major pediatric diseases including:
- Rare diseases
- Malignant tumors
- Severe infections
Marketed Status Requirements
- Must be approved for marketing in China
- Require at least 2 years of actual clinical use records
- Eligible product types:
- Chemical drugs
- Therapeutic biologics (excluding cell and gene therapy products)
- Traditional Chinese medicines
- Must have robust quality standards and manufacturing process control systems
Data Foundation Requirements
- Applicants must have preliminary clinical application data in pediatric populations, such as:
- Off-label use data
- Investigator-initiated clinical trial data
- OR have clear access to high-quality real-world data
Required Submission Materials
Applicants seeking communication and exchange with CDE must submit comprehensive documentation covering:
- Research background and rationale
- Real-world data sources and data fitness-for-use assessment
- Study design and statistical analysis plan
- Risk control and pharmacovigilance plan
- Study implementation and quality control
- Ethics and regulatory compliance
- Expected outcomes and regulatory communication plan
Market Impact & Strategic Implications
This draft guideline represents a significant step toward addressing the critical gap in pediatric drug availability in China, where an estimated 70% of medications used in children lack formal pediatric indications. By leveraging real-world evidence, the CDE aims to accelerate access to essential medicines while maintaining rigorous safety and efficacy standards.
For pharmaceutical companies with established adult products, this framework creates a lower-barrier pathway to expand into the pediatric market without conducting full-scale randomized controlled trials. Companies with robust real-world data collection systems and existing pediatric off-label use patterns stand to benefit most from this regulatory evolution.
The emphasis on rare diseases, pediatric cancers, and severe infections aligns with China’s broader healthcare priorities and may incentivize increased investment in these underserved therapeutic areas.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory developments and market opportunities. Actual implementation and impact may vary based on final guideline adoption, regulatory interpretations, and market dynamics.-Fineline Info & Tech